Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivospemin + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Panbela Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ivospemin + nab-paclitaxel + gemcitabine is a triple drug combination being evaluated as a treatment for metastatic pancreatic ductal adenocarcinoma. Ivospemin (code name SBP-101) is a polyamine analogue with a mechanism thought to disrupt tumor cell growth. Nab-paclitaxel is an albumin-bound formulation of paclitaxel that inhibits microtubule disassembly, and gemcitabine is a nucleoside analog that inhibits DNA synthesis by targeting DNA replication. The combination is believed to act synergistically, with ivospemin enhancing the cytotoxic effects of chemotherapy and nab-paclitaxel facilitating increased intratumoral concentration of gemcitabine by stromal depletion[5][7][9].
- Other names
- ivospemin + nab-paclitaxel + gemcitabine
02
Targets
DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))Polyamine transporter
Beyond the preview
Go deeper on ivospemin + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivospemin + nab-paclitaxel + gemcitabine.